Ipilimumab and tremelimumab as CTLA-4 inhibitors were used to treat patients with different cancers in clinical trials and led to prolonged overall survival (Author Anonymous, 2010; Hodi et al., 2010; Kyriakidis et al., 2021), but with limited off-label use in AML. Here, CTLA4 is linked to acute myeloid leukemia.